[From PRNewswire] Singapore-based SCG Cell Therapy Pte Ltd (“SCG”) presented interim data from an investigator-initiated clinical trial of SCG101 at the International Liver Congress 2022 Annual Meeting in London on 23 June. This included data evaluating single dose SCG101 in patients with advanced hepatitis B (HBV) related hepatocellular carcinoma (HCC). HCC is the most common type of liver cancer. SCG101 can advance further improvements in immunotherapy for liver cancer in Singapore.
What is SCG101
SCG101 is an autologous T-cell receptor (TCR) T cell therapy that incorporates SCG’s proprietary technology. It is an investigational cell therapy product that targets specific epitopes of hepatitis B surface antigen (HBsAg). In 2022, the China National Medical Products Administration and Singapore Health Science Authority granted clinical trial approvals for SCG101 to be used for potential treatment of HBV-related HCC.
Clinic Trial Shows Encouraging Possibilities for Immunotherapy for Liver Cancer
The trail results showed significant antiviral activity and tumour control in two of three patients. Tumour growth was controlled in two out of three patients with lesion shrinkage observed. In addition, there is rapid and significant serum HBsAg reduction observed in both subjects.
“The results of SCG101 show for the first time that an HBsAg directed TCR T cell therapy can provide dual benefit of antiviral and tumour control to patients with HBV-related HCC,” said Shunda Du, MD, hepatologist, Peking Union Medical College and principal investigator for the trial.
The trail showed also that “the safety profile of SCG101 was consistent with the side effects expected in T cell therapy”. Also, “(t)here was no neurotoxicity observed and also no treatment-related AE or SAE (Adverse Event or Serious Adverse Event) which led to treatment discontinuation.”
Liver Cancer Statistics
It is estimated that in 2020, there were more than 905,000 new cases of liver cancer and more than 830,100 deaths from the disease globally.Liver cancer in Singapore was the 4th most commonly occurring cancer for males for the period 2015-2019. It was ranked 3rd in terms of mortality for males. Liver cancer was not among the top 10 cancers for females in terms of mortality, but in terms of mortality, it ranked 5th.
About SCG Cell Therapy
SCG is a leading biotechnology company focusing on the development of novel immunotherapies for infections and their associated cancers. The company targets the most common cancer-causing infections: helicobacter pylori, human papillomavirus, and hepatitis B, and develops a broad and unique pipeline of T cell therapies, antibodies, and therapeutic vaccines against infections to prevent and cure its associated cancers.
Established and headquartered in Singapore, SCG combines regional advantages in Singapore, China and Germany, covering the entire value chain from innovative drug research and discovery, manufacturing, clinical development and commercialization. SCG collaborates with leading scientists and researchers to bring first-in-class and best-in-class medical products/technologies to enhance innovation in medical product development.
Protect against cancer, cardiovascular disease, and other chronic diseases with regular health screening. Compare and shop for health screenings from Singapore and regional healthcare providers at a single convenient platform - shop.health365.sg
This article is informative only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment, and should never be relied upon for specific medical advice.
